<DOC>
	<DOC>NCT01664533</DOC>
	<brief_summary>This prospective, multicenter observational study will evaluate the efficacy, safety, and tolerability of Tarceva (erlotinib) as second-line treatment in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed after pemetrexed-containing first-line chemotherapy. Eligible patients will be followed until withdrawal of consent, lost-to-follow-up, or study termination, whichever occurs first.</brief_summary>
	<brief_title>An Observational Study of Erlotinib (Tarceva) as Second-line Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Failure of Pemetrexed in First-line Therapy</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Adult patients â‰¥ 18 years of age. Histologically or cytologically documented locally advanced or metastatic nonsmall cell lung cancer (inoperable Stage III or IV according to the 7th TNM Classification of Malignant Tumors). Experiencing disease progression after pemetrexedcontaining firstline chemotherapy regimen. Eastern Cooperative Oncology Group (ECOG) performance status 02. Initiated on secondline treatment with Tarceva at the most 4 weeks prior to study entry at baseline (date of signature of informed consent). Prior chemotherapy/targeted therapy after disease progression after firstline treatment in the advanced nonsmall cell lung cancer (NSCLC) setting. Contraindication for Tarceva according to the Summary of Product characteristics.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>